The Harnett Labs
“I have 30 years of experience of working on the immunology of parasitic worms, starting during my PhD at the University of Glasgow, then spending 8 years at the National Institute for Medical Research in London before returning to Glasgow to the University of Strathclyde. During the past 10-15 years I have been investigating the therapeutic potential of the ES-62 molecule in a range of diseases including asthma, rheumatoid arthritis, systemic lupus erythematosus and cardiovascular disease. With respect to asthma, my findings include the first demonstration that a single molecule derived from a parasitic worm – ES-62 – could inhibit the development of asthma in mice and block isolated human cells from releasing the chemicals, which cause allergy."
“I studied for my PhD in Madrid, focusing on the biology of neglected tropical diseases in South America. After completing my PhD I decided to continue my scientific career at the University of Glasgow, where I have worked for the last 6 years studying the cause of autoimmune diseases, such as lupus or rheumatoid arthritis. I have also worked more recently in the field of Asthma in collaboration with Prof Harnett and his group at the University of Strathclyde and I would mow like to start up my own research line to understand how inflammatory diseases work and to find alternative drugs that we can translate to the clinic”.
Miguel Pineda PhD
Professor William Harnett
"I have been working on the signalling mechanism underpinning development of the immune response for some 30 years, in order to identify novel drug targets and immunomodulatory therapies to combat infection and inflammatory disease. I started with my PhD at the University of Glasgow on pathways of pathogen biology before working on innate cell, particularly neutrophil, responses and their dysfunction in diseases at University College London and then adaptive B and T cell Biology at the National Institute for Medicine, London. Since my return to the University of Glasgow, a major focus has been to identify the targets of the anti-inflammatory actions of ES-62 in order to identify Biomarkers of inflammatory disease and potential sites of intervention in Asthma, Rheumatoid arthritis, Systemic Lupus Erythematosus and Cardiovascular Disease."
"I obtained my PhD in Osteoimmunology in 2014 and my studies focused on the role of antibody-mediated interactions on the differentiation of bone eroding cells – Osteoclasts –in osteoporosis and arthritis. Since then I have been working to understand how ES-62 can be used to modulate the immune response in models of allergy and autoimmune disease. I have been particularly interested in the effect of the ES-62 molecule in the pathogenesis of Multiple Sclerosis."
James Doonan PhD
Post Doctoral Reseachers
"I obtained my master degree in 2012 in biochemistry at University of Manchester . I worked in two six month projects focusing generally on some aspects of structural biology . First project was about " EXPRESSION, PURIFICATION AND CHARACTERIZATION OF KILLIFISH CFTR C-TERMINAL REGION " in Prof. Robert Ford lab and the second was about " Designer proteins for human disease therapy " in Dr Lydia Tabernero lab. I am now doing a PhD in Prof. William Harnett’s lab on " Metabolomic profiling of the effects of synthetic analogues of the parasitic worm product ES-62 on immune cells" focusing on the potential roles of affected metabolites in inflammatory process."
In 2015, I completed my PhD at the University of Strathclyde, during which I studied how the protozoan parasite, Leishmania mexicana, can suppress the migration of dendritic cells and how this modulates the immune response. Following my PhD, I joined Prof. Margaret Harnett’s group at the University of Glasgow, and began investigating whether the anti-inflammatory worm product, ES-62, can extend life and healthspan by suppressing age associated low grade inflammation and metabolic dysregulation. Working in collaboration with the University of Strathclyde and Glasgow Ageing Research Network, we ultimately hope to determine whether ES-62 can protect against common age associated disease and improve later life health.
Jenny Crowe PhD
Felicity Lumb PhD
"I have recently obtained my PhD in Immunology working in Prof. William Harnett’s group at the University of Strathclyde. My studies identified small drug-like analogues of ES-62 that mimic the anti-inflammatory effect of ES-62 on a specific immune cell, the dendritic cell. Dendritic cells act as sentinels of the immune system and can activate and guide the immune response to infection and modifying their activation is a key mechanism by which ES-62 promotes its anti-inflammatory effects. I am now working, in collaboration with Prof. Margaret Harnett’s group, on a new project investigating the potential of ES-62 to slow ageing and to improve late-life health and well-being."
I obtained my Ph.D. at Ulster University (Northern Ireland) in 2012 investigating the role of canonical wnt signalling during lineage commitment in embryonic stem cells and haematopoiesis. While carrying out my PhD that I became particularly interested in understanding signalling networks and their (de-) regulation in different disease models. This interest was cemented during my post-doctoral roles at the University of Glasgow where I focussed on evaluating immunomodulation in chronic myeloid leukaemia followed by another post-doc set up to understand the molecular pathogenesis of chronic lymphoid leukaemia with a view of identifying novel therapeutic targets utilising in vitro and in vivo disease models. I joined the Harnett lab in October 2016 in an Arthritis Research UK (ARUK) funded project where I am investigating the role of excretory/secretory immunomodulatory products from parasitic worms in providing protection against musculoskeletal diseases such as rheumatoid arthritis (RA) by impacting on the host microbiome.
Anuradha Tarafdar PhD